Excel Drug-Eluting Stent Pilot Clinical Registry

Excel Drug-Eluting Stent Pilot Clinical Registry

The Trial aims to evaluate long-term efficiency of Excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.

30-day, 6-month, and 12-month clinical follow-up and 6 to 9-month IVUS or SCA follow-up to measure long-term efficiency of Excel stent in the inhibition of restenosis as well as the safety after the cessation of the 6-month anti-platelet drug treatment.

Inclusion Criteria:

• Patients who should fulfill with criteria of implanting Excel stents.
• Each patient enrolled is only allowed to implant Excel stents.
• Each patient are not allowed to be implanted more than 6 Excel stents.Also, 3 over-lapped stents are not allowed to be implanted in the same vessel(3-5mm overlapping needed; length of stents totally are not allowed to be over 80mm; fully post-dilated is essential for overlapping).
• Patients acknowlegement to the trial is essential.

Exclusion Criteria:

• AMI withine 1 week.
• Patients who do not suitable to Excel stenting.(For example, non-tolerant to anti-platelet drug or cardiac/non-cardiac surgery undergoing recently.)
• Patients who have multiple branch lesions can not apply single Excel stenting.
• Patients who refuse to sign the Trial Acknowledgement.
• Patients with intra-stent restenosis.